{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:59:56Z","timestamp":1793915996191,"version":"4.8.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41573-026-01450-2","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:39:26Z","timestamp":1779964766000},"page":"723-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting claudins in cancer"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-0155","authenticated-orcid":false,"given":"Yuki","family":"Niwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuo","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1450_CR1","first-page":"71","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71\u201396 (2008).","journal-title":"CA Cancer J. Clin."},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1083\/jcb.143.2.391","volume":"143","author":"M Furuse","year":"1998","unstructured":"Furuse, M., Sasaki, H., Fujimoto, K. & Tsukita, S. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 143, 391\u2013401 (1998). This study demonstrated that expression of a single claudin gene (CLDN-1 or CLDN-2) is sufficient to reconstitute tight junction strand networks and recruit occludin in fibroblasts, establishing claudins as the core structural components of tight junctions.","journal-title":"J. Cell Biol."},{"key":"1450_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","volume":"141","author":"M Furuse","year":"1998","unstructured":"Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K. & Tsukita, S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539\u20131550 (1998).","journal-title":"J. Cell Biol."},{"key":"1450_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1083\/jcb.147.1.195","volume":"147","author":"N Sonoda","year":"1999","unstructured":"Sonoda, N. et al. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 147, 195\u2013204 (1999). This study provided direct evidence that specific claudins are essential components of tight junction barrier function by showing that a Clostridium perfringens enterotoxin C-terminal fragment selectively removes CLND-3 and CLDN-4 from tight junction strands, leading to barrier disruption.","journal-title":"J. Cell Biol."},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1083\/jcb.136.6.1239","volume":"136","author":"J Katahira","year":"1997","unstructured":"Katahira, J., Inoue, N., Horiguchi, Y., Matsuda, M. & Sugimoto, N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell Biol. 136, 1239\u20131247 (1997). This study was the first to clone and functionally characterize the host cell receptor for Clostridium perfringens enterotoxin, establishing the molecular basis for toxin binding and its role in disrupting tight junctions via claudin family interactions.","journal-title":"J. Cell Biol."},{"key":"1450_CR6","first-page":"1819","volume":"13","author":"TM Gress","year":"1996","unstructured":"Gress, T. M. et al. A pancreatic cancer-specific expression profile. Oncogene 13, 1819\u20131830 (1996).","journal-title":"Oncogene"},{"key":"1450_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/(SICI)1098-2264(199909)26:1<70::AID-GCC10>3.0.CO;2-A","volume":"26","author":"MM Geng","year":"1999","unstructured":"Geng, M. M. et al. Use of representational difference analysis to study the effect of TGFB on the expression profile of a pancreatic cancer cell line. Genes Chromosomes Cancer 26, 70\u201379 (1999).","journal-title":"Genes Chromosomes Cancer"},{"key":"1450_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/gast.2001.27124","volume":"121","author":"P Michl","year":"2001","unstructured":"Michl, P. et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121, 678\u2013684 (2001).","journal-title":"Gastroenterology"},{"key":"1450_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.drudis.2007.11.005","volume":"13","author":"M Kondoh","year":"2008","unstructured":"Kondoh, M., Yoshida, T., Kakutani, H. & Yagi, K. Targeting tight junction proteins \u2014 significance for drug development. Drug. Discov. Today 13, 180\u2013186 (2008).","journal-title":"Drug. Discov. Today"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","volume":"44","author":"S Tsukita","year":"2019","unstructured":"Tsukita, S., Tanaka, H. & Tamura, A. The claudins: from tight junctions to biological systems. Trends Biochem. Sci. 44, 141\u2013152 (2019).","journal-title":"Trends Biochem. Sci."},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00424-016-1878-6","volume":"469","author":"Y Hashimoto","year":"2017","unstructured":"Hashimoto, Y., Yagi, K. & Kondoh, M. Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers. Pflug. Arch. 469, 45\u201353 (2017).","journal-title":"Pflug. Arch."},{"key":"1450_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023). This phase III trial established CLDN-18.2 as a clinically actionable target by showing survival benefit of zolbetuximab plus chemotherapy in gastric cancer.","journal-title":"Lancet"},{"key":"1450_CR13","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner, S. J. et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 29, 3882\u20133891 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1450_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","volume":"29","author":"MSJ McDermott","year":"2023","unstructured":"McDermott, M. S. J. et al. Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors. Clin. Cancer Res. 29, 2131\u20132143 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1450_CR15","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023). This phase III trial confirmed CLDN-18.2 as a clinically relevant target by demonstrating survival benefit of zolbetuximab in advanced gastric cancer.","journal-title":"Nat. Med."},{"key":"1450_CR16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(23)00732-8","volume":"401","author":"HWM van Laarhoven","year":"2023","unstructured":"van Laarhoven, H. W. M. & Derks, S. Claudin-18.2 targeting by zolbetuximab: results of SPOTLIGHT in perspective. Lancet 401, 1630\u20131631 (2023).","journal-title":"Lancet"},{"key":"1450_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44874-0","volume":"9","author":"G Zhu","year":"2019","unstructured":"Zhu, G. et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci. Rep. 9, 8420 (2019).","journal-title":"Sci. Rep."},{"key":"1450_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang, H. et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J. Natl Cancer Inst. 111, 409\u2013418 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1450_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.febslet.2011.01.028","volume":"585","author":"K Mineta","year":"2011","unstructured":"Mineta, K. et al. Predicted expansion of the claudin multigene family. FEBS Lett. 585, 606\u2013612 (2011).","journal-title":"FEBS Lett."},{"key":"1450_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1073\/pnas.96.2.511","volume":"96","author":"K Morita","year":"1999","unstructured":"Morita, K., Furuse, M., Fujimoto, K. & Tsukita, S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl Acad. Sci. USA 96, 511\u2013516 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1450_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.1248571","volume":"344","author":"H Suzuki","year":"2014","unstructured":"Suzuki, H. et al. Crystal structure of a claudin provides insight into the architecture of tight junctions. Science 344, 304\u2013307 (2014). This study provided the first high-resolution crystal structure of a mammalian claudin, revealing key architectural features of tight junction proteins and offering structural insight into how claudins form paracellular ion pathways.","journal-title":"Science"},{"key":"1450_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1083\/jcb.147.6.1351","volume":"147","author":"M Itoh","year":"1999","unstructured":"Itoh, M. et al. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell Biol. 147, 1351\u20131363 (1999).","journal-title":"J. Cell Biol."},{"key":"1450_CR23","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1242\/jcs.114.18.3219","volume":"114","author":"BZ Harris","year":"2001","unstructured":"Harris, B. Z. & Lim, W. A. Mechanism and role of PDZ domains in signaling complex assembly. J. Cell Sci. 114, 3219\u20133231 (2001).","journal-title":"J. Cell Sci."},{"key":"1450_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/35067088","volume":"2","author":"S Tsukita","year":"2001","unstructured":"Tsukita, S., Furuse, M. & Itoh, M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285\u2013293 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1450_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/nyas.13371","volume":"1397","author":"H Suzuki","year":"2017","unstructured":"Suzuki, H., Tani, K. & Fujiyoshi, Y. Crystal structures of claudins: insights into their intermolecular interactions. Ann. NY Acad. Sci. 1397, 25\u201334 (2017).","journal-title":"Ann. NY Acad. Sci."},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1083\/jcb.147.1.185","volume":"147","author":"K Morita","year":"1999","unstructured":"Morita, K., Sasaki, H., Furuse, M. & Tsukita, S. Endothelial claudin: claudin-5\/TMVCF constitutes tight junction strands in endothelial cells. J. Cell Biol. 147, 185\u2013194 (1999).","journal-title":"J. Cell Biol."},{"key":"1450_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0092-8674(00)81553-6","volume":"99","author":"A Gow","year":"1999","unstructured":"Gow, A. et al. CNS myelin and Sertoli cell tight junction strands are absent in Osp\/claudin-11 null mice. Cell 99, 649\u2013659 (1999).","journal-title":"Cell"},{"key":"1450_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1152\/physrev.00019.2012","volume":"93","author":"D G\u00fcnzel","year":"2013","unstructured":"G\u00fcnzel, D. & Yu, A. S. Claudins and the modulation of tight junction permeability. Physiol. Rev. 93, 525\u2013569 (2013).","journal-title":"Physiol. Rev."},{"key":"1450_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.semcdb.2014.09.019","volume":"36","author":"A Tamura","year":"2014","unstructured":"Tamura, A. & Tsukita, S. Paracellular barrier and channel functions of TJ claudins in organizing biological systems: advances in the field of barriology revealed in knockout mice. Semin. Cell Dev. Biol. 36, 177\u2013185 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1450_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1083\/jcb.200302070","volume":"161","author":"T Nitta","year":"2003","unstructured":"Nitta, T. et al. Size-selective loosening of the blood\u2013brain barrier in claudin-5-deficient mice. J. Cell Biol. 161, 653\u2013660 (2003).","journal-title":"J. Cell Biol."},{"key":"1450_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1083\/jcb.200110122","volume":"156","author":"M Furuse","year":"2002","unstructured":"Furuse, M. et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J. Cell Biol. 156, 1099\u20131111 (2002).","journal-title":"J. Cell Biol."},{"key":"1450_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.gastro.2012.10.035","volume":"144","author":"M Wada","year":"2013","unstructured":"Wada, M., Tamura, A., Takahashi, N. & Tsukita, S. Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology 144, 369\u2013380 (2013).","journal-title":"Gastroenterology"},{"key":"1450_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2010.08.006","volume":"140","author":"A Tamura","year":"2011","unstructured":"Tamura, A. et al. Loss of Claudin-15, but not Claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine. Gastroenterology 140, 913\u2013923 (2011).","journal-title":"Gastroenterology"},{"key":"1450_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.285.5424.103","volume":"285","author":"DB Simon","year":"1999","unstructured":"Simon, D. B. et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285, 103\u2013106 (1999).","journal-title":"Science"},{"key":"1450_CR35","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/brain\/awac215","volume":"145","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto, Y. et al. Recurrent de novo mutations in CLDN5 induce an anion-selective blood\u2013brain barrier and alternating hemiplegia. Brain 145, 3374\u20133382 (2022).","journal-title":"Brain"},{"key":"1450_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(01)00200-8","volume":"104","author":"ER Wilcox","year":"2001","unstructured":"Wilcox, E. R. et al. Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29. Cell 104, 165\u2013172 (2001).","journal-title":"Cell"},{"key":"1450_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx7431","volume":"11","author":"H Kashihara","year":"2025","unstructured":"Kashihara, H. et al. Functional landscape of mechanistic diversity in 27 claudin family members at tight junctions. Sci. Adv. 11, eadx7431 (2025). This study systematically defines the functional diversity of all 27 claudin family members by reconstituting individual claudins in claudin-null epithelial cells, revealing distinct barrier and channel properties and a new classification framework that advances our mechanistic understanding of tight junction diversity and its physiological importance.","journal-title":"Sci. Adv."},{"key":"1450_CR38","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1083\/jcb.201812157","volume":"218","author":"T Otani","year":"2019","unstructured":"Otani, T. et al. Claudins and JAM-A coordinately regulate tight junction formation and epithelial polarity. J. Cell Biol. 218, 3372\u20133396 (2019).","journal-title":"J. Cell Biol."},{"key":"1450_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217561120","volume":"120","author":"K Shigetomi","year":"2023","unstructured":"Shigetomi, K., Ono, Y., Matsuzawa, K. & Ikenouchi, J. Cholesterol-rich domain formation mediated by ZO proteins is essential for tight junction formation. Proc. Natl Acad. Sci. USA 120, e2217561120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1450_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91464-0","volume":"11","author":"M Watanabe","year":"2021","unstructured":"Watanabe, M. et al. CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma. Sci. Rep. 11, 12554 (2021).","journal-title":"Sci. Rep."},{"key":"1450_CR41","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.3390\/ijms22073774","volume":"22","author":"A Rahman","year":"2021","unstructured":"Rahman, A. et al. Reduced Claudin-12 expression predicts poor prognosis in cervical cancer. Int. J. Mol. Sci. 22, 3774 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1450_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.783016","volume":"13","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Evaluation of the prognostic relevance of differential claudin gene expression highlights Claudin-4 as being suppressed by TGF\u03b21 inhibitor in colorectal cancer. Front. Genet. 13, 783016 (2022).","journal-title":"Front. Genet."},{"key":"1450_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","volume":"2","author":"W Ma","year":"2021","unstructured":"Ma, W. et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat. Cancer 2, 83\u201397 (2021).","journal-title":"Nat. Cancer"},{"key":"1450_CR44","first-page":"5552","volume":"12","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Claudin 19 inhibits the malignant potential of breast cancer cells by modulating extracellular matrix-associated UBE2C\/Wnt signaling. Am. J. Cancer Res. 12, 5552\u20135563 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"1450_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113523","volume":"426","author":"MF Paes","year":"2023","unstructured":"Paes, M. F. et al. Overexpression of CLDN16 in ovarian cancer is modulated by PI3K and PKC pathways. Exp. Cell Res. 426, 113523 (2023).","journal-title":"Exp. Cell Res."},{"key":"1450_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04248-7","volume":"21","author":"S Huang","year":"2023","unstructured":"Huang, S. et al. Downregulation of claudin5 promotes malignant progression and radioresistance through Beclin1-mediated autophagy in esophageal squamous cell carcinoma. J. Transl. Med. 21, 379 (2023).","journal-title":"J. Transl. Med."},{"key":"1450_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1051497","volume":"12","author":"DW Wang","year":"2022","unstructured":"Wang, D. W., Zhang, W. H., Danil, G., Yang, K. & Hu, J. K. The role and mechanism of claudins in cancer. Front. Oncol. 12, 1051497 (2022).","journal-title":"Front. Oncol."},{"key":"1450_CR48","first-page":"6265","volume":"63","author":"P Michl","year":"2003","unstructured":"Michl, P. et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 63, 6265\u20136271 (2003).","journal-title":"Cancer Res."},{"key":"1450_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1541-7786.MCR-18-0531","volume":"17","author":"I Romero-Calvo","year":"2019","unstructured":"Romero-Calvo, I. et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors. Mol. Cancer Res. 17, 70\u201383 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1450_CR50","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.1245\/s10434-011-1970-2","volume":"19","author":"K Tsutsumi","year":"2012","unstructured":"Tsutsumi, K. et al. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 19, S491\u2013S499 (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"1450_CR51","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1016\/j.febslet.2005.09.091","volume":"579","author":"SS de Oliveira","year":"2005","unstructured":"de Oliveira, S. S., de Oliveira, I. M., De Souza, W. & Morgado-D\u00edaz, J. A. Claudins upregulation in human colorectal cancer. FEBS Lett. 579, 6179\u20136185 (2005).","journal-title":"FEBS Lett."},{"key":"1450_CR52","doi-asserted-by":"publisher","first-page":"42375","DOI":"10.1074\/jbc.M503786200","volume":"280","author":"M Tanaka","year":"2005","unstructured":"Tanaka, M., Kamata, R. & Sakai, R. EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability. J. Biol. Chem. 280, 42375\u201342382 (2005).","journal-title":"J. Biol. Chem."},{"key":"1450_CR53","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.3390\/ijms21218340","volume":"21","author":"T Owari","year":"2020","unstructured":"Owari, T. et al. Role of nuclear claudin-4 in renal cell carcinoma. Int. J. Mol. Sci. 21, 8340 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1450_CR54","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.humpath.2005.05.019","volume":"36","author":"MB Resnick","year":"2005","unstructured":"Resnick, M. B. et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum. Pathol. 36, 886\u2013892 (2005).","journal-title":"Hum. Pathol."},{"key":"1450_CR55","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1172\/JCI24543","volume":"115","author":"P Dhawan","year":"2005","unstructured":"Dhawan, P. et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest. 115, 1765\u20131776 (2005).","journal-title":"J. Clin. Invest."},{"key":"1450_CR56","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/pros.20578","volume":"67","author":"M Krajewska","year":"2007","unstructured":"Krajewska, M., Olson, A. H., Mercola, D., Reed, J. C. & Krajewski, S. Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate. Prostate 67, 907\u2013910 (2007).","journal-title":"Prostate"},{"key":"1450_CR57","first-page":"139","volume":"20","author":"S Morohashi","year":"2007","unstructured":"Morohashi, S. et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int. J. Mol. Med. 20, 139\u2013143 (2007).","journal-title":"Int. J. Mol. Med."},{"key":"1450_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cbf.3489","volume":"38","author":"L Huang","year":"2020","unstructured":"Huang, L. et al. Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR\/AKT\/mTOR signalling pathway in hepatocellular carcinoma. Cell Biochem. Funct. 38, 541\u2013548 (2020).","journal-title":"Cell Biochem. Funct."},{"key":"1450_CR59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/nyas.13346","volume":"1397","author":"SM Stamatovic","year":"2017","unstructured":"Stamatovic, S. M., Johnson, A. M., Sladojevic, N., Keep, R. F. & Andjelkovic, A. V. Endocytosis of tight junction proteins and the regulation of degradation and recycling. Ann. NY Acad. Sci. 1397, 54\u201365 (2017).","journal-title":"Ann. NY Acad. Sci."},{"key":"1450_CR60","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1091\/mbc.e11-04-0343","volume":"22","author":"JD Dukes","year":"2011","unstructured":"Dukes, J. D. et al. Functional ESCRT machinery is required for constitutive recycling of claudin-1 and maintenance of polarity in vertebrate epithelial cells. Mol. Biol. Cell 22, 3192\u20133205 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"1450_CR61","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/0008-5472.CAN-06-1680","volume":"67","author":"SR Shiou","year":"2007","unstructured":"Shiou, S. R. et al. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res. 67, 1571\u20131579 (2007).","journal-title":"Cancer Res."},{"key":"1450_CR62","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/sj.onc.1210155","volume":"26","author":"PD Leotlela","year":"2007","unstructured":"Leotlela, P. D. et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 26, 3846\u20133856 (2007).","journal-title":"Oncogene"},{"key":"1450_CR63","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1450_CR64","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1538-7445.AM2020-5183","volume":"80","author":"T Fei","year":"2020","unstructured":"Fei, T. et al. The preclinical characterization of TST001, a novel humanized anti-Claudin18.2 mAb with enhanced binding affinity and anti-tumor activity. Cancer Res. 80, 5183 (2020).","journal-title":"Cancer Res."},{"key":"1450_CR65","doi-asserted-by":"publisher","first-page":"CT132","DOI":"10.1158\/1538-7445.AM2024-CT132","volume":"84","author":"Y Janjigian","year":"2024","unstructured":"Janjigian, Y. et al. A phase I\/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of osemitamab administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors. Cancer Res. 84, CT132 (2024).","journal-title":"Cancer Res."},{"key":"1450_CR66","doi-asserted-by":"publisher","first-page":"S885","DOI":"10.1016\/j.annonc.2024.08.1485","volume":"35","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G\/GEJ cancer (TranStar102). Ann. Oncol. 35, S885 (2024).","journal-title":"Ann. Oncol."},{"key":"1450_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. CMG901, a claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep. Med. 5, 101710 (2024).","journal-title":"Cell Rep. Med."},{"key":"1450_CR68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan, D. Y. et al. Claudin 18.2-targeting antibody\u2013drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 26, 227\u2013238 (2025).","journal-title":"Lancet Oncol."},{"key":"1450_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03783-8","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. CLDN18.2-targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03783-8 (2025).","journal-title":"Nat. Med."},{"key":"1450_CR70","doi-asserted-by":"publisher","unstructured":"Wang, Y., Gong, J., Qu, X. & Shen, L. A phase II trial of bispecific antibody Q-1802 in patients with relapsed or refractory solid tumors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1500 (2024).","DOI":"10.1136\/jitc-2024-SITC2024.1500"},{"key":"1450_CR71","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1538-7445.AM2022-4260","volume":"82","author":"J Li","year":"2022","unstructured":"Li, J. et al. PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody constructed with the PACbody and SPECpair technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model. Cancer Res. 82, 4260 (2022).","journal-title":"Cancer Res."},{"key":"1450_CR72","doi-asserted-by":"publisher","first-page":"S933","DOI":"10.1016\/j.annonc.2024.08.1594","volume":"35","author":"MJ Overman","year":"2024","unstructured":"Overman, M. J. et al. TWINPEAK phase I\/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and\/or pembrolizumab in gastric\/GEJ-carcinomas or PDAC. Ann. Oncol. 35, S933\u2013S934 (2024).","journal-title":"Ann. Oncol."},{"key":"1450_CR73","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","volume":"83","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa, T. et al. ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models. Cancer Res. 83, 2962 (2023).","journal-title":"Cancer Res."},{"key":"1450_CR74","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2023.06.037","volume":"165","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. CLDN18.2 BiTE engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer. Gastroenterology 165, 1219\u20131232 (2023).","journal-title":"Gastroenterology"},{"key":"1450_CR75","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","volume":"43","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Safety and efficacy of QLS31905 in patients with advanced solid tumors: updated data from phase 1 study. J. Clin. Oncol. 43, 2527 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR76","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2024.42.16_suppl.2519","volume":"42","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. J. Clin. Oncol. 42, 2519 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011857","volume":"13","author":"M Gasper","year":"2025","unstructured":"Gasper, M. et al. An affinity-modulated T cell engager targeting claudin 18.2 shows potent anti-tumor activity with limited cytokine release. J. Immunother. Cancer 13, e011857 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1450_CR78","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2024.42.16_suppl.4011","volume":"42","author":"J Hao","year":"2024","unstructured":"Hao, J. et al. Safety and efficacy of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: preliminary results from a phase 1 study. J. Clin. Oncol. 42, 4011 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR79","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"1450_CR80","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049\u20132060 (2025).","journal-title":"Lancet"},{"key":"1450_CR81","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0138","author":"SX Xu","year":"2024","unstructured":"Xu, S. X. et al. Preclinical development of T cells engineered to express a T cell antigen coupler (TAC) targeting claudin 18.2-positive solid tumors. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0138 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1450_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15074","volume":"42","author":"X Yu","year":"2024","unstructured":"Yu, X., Zhang, J. & Liu, J. A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+ T cells in patients with advanced solid tumors. J. Clin. Oncol. 42, e15074 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR83","doi-asserted-by":"publisher","first-page":"TPS2670","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2670","volume":"41","author":"KP Papadopoulos","year":"2023","unstructured":"Papadopoulos, K. P. et al. A phase I\/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors. J. Clin. Oncol. 41, TPS2670 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100844","volume":"38","author":"SP Stratton","year":"2025","unstructured":"Stratton, S. P. et al. Analytical and clinical performance of the VENTANA CLDN18 (43-14A) RxDx assay in gastric and gastroesophageal junction adenocarcinoma tissue samples in SPOTLIGHT and GLOW. Mod. Pathol. 38, 100844 (2025). This study validated the VENTANA CLDN-18 (43-14A) RxDx immunohistochemistry assay as a robust companion diagnostic for identifying CLDN-18.2-positive gastric and gastro-oesophageal junction adenocarcinomas in the SPOTLIGHT and GLOW trials, enabling accurate patient selection for zolbetuximab therapy.","journal-title":"Mod. Pathol."},{"key":"1450_CR85","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 32, 609\u2013619 (2021).","journal-title":"Ann. Oncol."},{"key":"1450_CR86","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1535-7163.MCT-23-0353","volume":"22","author":"NA O\u2019Brien","year":"2023","unstructured":"O\u2019Brien, N. A. et al. Development of a novel CLDN18.2-directed monoclonal antibody and antibody\u2013drug conjugate for treatment of CLDN18.2-positive cancers. Mol. Cancer Ther. 22, 1365\u20131375 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"1450_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2992","volume":"4","author":"U Ben-David","year":"2013","unstructured":"Ben-David, U., Nudel, N. & Benvenisty, N. Immunologic and chemical targeting of the tight-junction protein claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat. Commun. 4, 1992 (2013).","journal-title":"Nat. Commun."},{"key":"1450_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105665","volume":"25","author":"B Screnci","year":"2022","unstructured":"Screnci, B. et al. Antibody specificity against highly conserved membrane protein claudin 6 driven by single atomic contact point. iScience 25, 105665 (2022).","journal-title":"iScience"},{"key":"1450_CR89","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s10637-022-01276-w","volume":"40","author":"N Adra","year":"2022","unstructured":"Adra, N. et al. A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. Invest. New Drugs 40, 1087\u20131094 (2022).","journal-title":"Invest. New Drugs"},{"key":"1450_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR Stadler","year":"2024","unstructured":"Stadler, C. R. et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci. Transl. Med. 16, eadl2720 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1450_CR91","doi-asserted-by":"publisher","first-page":"TPS2669","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2669","volume":"41","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. A phase I\/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors. J. Clin. Oncol. 41, TPS2669 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR92","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1538-7445.AM2022-5202","volume":"82","author":"E Pham","year":"2022","unstructured":"Pham, E. et al. AMG 794, a claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE\u00ae) molecule for non-small cell lung cancer and epithelial ovarian cancer. Cancer Res. 82, 5202 (2022).","journal-title":"Cancer Res."},{"key":"1450_CR93","doi-asserted-by":"publisher","first-page":"721MO","DOI":"10.1016\/j.annonc.2024.08.783","volume":"35","author":"GE Konecny","year":"2024","unstructured":"Konecny, G. E. et al. Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors. Ann. Oncol. 35, 721MO (2024).","journal-title":"Ann. Oncol."},{"key":"1450_CR94","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3892\/ijmm.2024.5424","volume":"54","author":"M Katoh","year":"2024","unstructured":"Katoh, M. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer. Int. J. Mol. Med. 54, 100 (2024).","journal-title":"Int. J. Mol. Med."},{"key":"1450_CR95","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1450_CR96","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00262-004-0613-x","volume":"54","author":"S Offner","year":"2005","unstructured":"Offner, S. et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol. Immunother. 54, 431\u2013445 (2005).","journal-title":"Cancer Immunol. Immunother."},{"key":"1450_CR97","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0002-9440(10)63721-2","volume":"164","author":"SL Kominsky","year":"2004","unstructured":"Kominsky, S. L. et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol. 164, 1627\u20131633 (2004).","journal-title":"Am. J. Pathol."},{"key":"1450_CR98","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s002849900410","volume":"38","author":"FM Wallace","year":"1999","unstructured":"Wallace, F. M., Mach, A. S., Keller, A. M. & Lindsay, J. A. Evidence for Clostridium perfringens enterotoxin (CPE) inducing a mitogenic and cytokine response in vitro and a cytokine response in vivo. Curr. Microbiol. 38, 96\u2013100 (1999).","journal-title":"Curr. Microbiol."},{"key":"1450_CR99","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1158\/0008-5472.CAN-07-1314","volume":"67","author":"SL Kominsky","year":"2007","unstructured":"Kominsky, S. L. et al. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 67, 7977\u20137982 (2007).","journal-title":"Cancer Res."},{"key":"1450_CR100","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2967\/jnumed.120.243113","volume":"61","author":"JB Torres","year":"2020","unstructured":"Torres, J. B. et al. Radiolabeled cCPE peptides for SPECT imaging of claudin-4 overexpression in pancreatic cancer. J. Nucl. Med. 61, 1756\u20131763 (2020).","journal-title":"J. Nucl. Med."},{"key":"1450_CR101","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1124\/mol.109.058412","volume":"76","author":"R Saeki","year":"2009","unstructured":"Saeki, R. et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol. Pharmacol. 76, 918\u2013926 (2009).","journal-title":"Mol. Pharmacol."},{"key":"1450_CR102","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/jpet.110.168070","volume":"334","author":"R Saeki","year":"2010","unstructured":"Saeki, R. et al. A claudin-targeting molecule as an inhibitor of tumor metastasis. J. Pharmacol. Exp. Ther. 334, 576\u2013582 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1450_CR103","doi-asserted-by":"publisher","first-page":"12289","DOI":"10.3390\/ijms222212289","volume":"22","author":"S Alnajjar","year":"2021","unstructured":"Alnajjar, S. et al. Ablation of red stable transfected claudin expressing canine prostate adenocarcinoma and transitional cell carcinoma cell lines by C-CPE gold-nanoparticle-mediated laser intervention. Int. J. Mol. Sci. 22, 12289 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1450_CR104","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1158\/1078-0432.CCR-10-1644","volume":"17","author":"Z Gao","year":"2011","unstructured":"Gao, Z. et al. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and carboplatin. Clin. Cancer Res. 17, 1065\u20131074 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1450_CR105","first-page":"1323","volume":"12","author":"M Sato","year":"2024","unstructured":"Sato, M. et al. A novel bispecific antibody targeting CD137 and CLDN4 for treating patients with solid tumors. J. Immunother. Cancer 12, 1323 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1450_CR106","doi-asserted-by":"publisher","first-page":"TPS2670","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2670","volume":"42","author":"M Pelster","year":"2024","unstructured":"Pelster, M. et al. Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4. J. Clin. Oncol. 42, TPS2670 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1450_CR107","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ncb433","volume":"9","author":"A Wodarz","year":"2007","unstructured":"Wodarz, A. & N\u00e4thke, I. Cell polarity in development and cancer. Nat. Cell Biol. 9, 1016\u20131024 (2007).","journal-title":"Nat. Cell Biol."},{"key":"1450_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399406000056","volume":"8","author":"SL Kominsky","year":"2006","unstructured":"Kominsky, S. L. Claudins: emerging targets for cancer therapy. Expert. Rev. Mol. Med. 8, 1\u201311 (2006).","journal-title":"Expert. Rev. Mol. Med."},{"key":"1450_CR109","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jhep.2022.10.011","volume":"78","author":"N Roehlen","year":"2023","unstructured":"Roehlen, N. et al. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. J. Hepatol. 78, 343\u2013355 (2023).","journal-title":"J. Hepatol."},{"key":"1450_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj4221","volume":"14","author":"N Roehlen","year":"2022","unstructured":"Roehlen, N. et al. A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity. Sci. Transl. Med. 14, eabj4221 (2022). This study showed that a monoclonal antibody targeting non-junctional CLDN-1 suppresses fibrosis in patient-derived and animal models by modulating cell plasticity, providing preclinical proof of concept for CLDN-1-targeted antifibrotic therapy.","journal-title":"Sci. Transl. Med."},{"key":"1450_CR111","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167310","volume":"8","author":"K Sugiura","year":"2023","unstructured":"Sugiura, K. et al. LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3. JCI Insight 8, e167310 (2023).","journal-title":"JCI Insight"},{"key":"1450_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100305","volume":"16","author":"A Toso","year":"2022","unstructured":"Toso, A. et al. CLAUDIN-1 targeting antibodies in solid tumors: from ALE.C04 to CLAUDIN-1 oncology platform. Immunooncol Technol. 16, 100305 (2022).","journal-title":"Immunooncol Technol."},{"key":"1450_CR113","doi-asserted-by":"publisher","first-page":"LB284","DOI":"10.1158\/1538-7445.AM2023-LB284","volume":"83","author":"A Toso","year":"2023","unstructured":"Toso, A. et al. CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors. Cancer Res. 83, LB284 (2023).","journal-title":"Cancer Res."},{"key":"1450_CR114","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1158\/0008-5472.CAN-21-3896","volume":"82","author":"H Cao","year":"2022","unstructured":"Cao, H. et al. Claudin-12 deficiency inhibits tumor growth by impairing transendothelial migration of myeloid-derived suppressor cells. Cancer Res. 82, 2472\u20132484 (2022).","journal-title":"Cancer Res."},{"key":"1450_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81023-y","volume":"11","author":"C Ikeda","year":"2021","unstructured":"Ikeda, C. et al. Utility of claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Sci. Rep. 11, 1195 (2021).","journal-title":"Sci. Rep."},{"key":"1450_CR116","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s42003-021-02189-9","volume":"4","author":"S Tabari\u00e8s","year":"2021","unstructured":"Tabari\u00e8s, S. et al. Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Commun. Biol. 4, 657 (2021).","journal-title":"Commun. Biol."},{"key":"1450_CR117","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.3390\/cancers14205026","volume":"14","author":"M Lemesle","year":"2022","unstructured":"Lemesle, M. et al. CLDN1 sensitizes triple-negative breast cancer cells to chemotherapy. Cancers 14, 5026 (2022).","journal-title":"Cancers"},{"key":"1450_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.595436","volume":"12","author":"P Gao","year":"2021","unstructured":"Gao, P. et al. Association of CLDN6 and CLDN10 with immune microenvironment in ovarian cancer: a study of the claudin family. Front. Genet. 12, 595436 (2021).","journal-title":"Front. Genet."},{"key":"1450_CR119","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1111\/cas.15057","volume":"112","author":"F Ren","year":"2021","unstructured":"Ren, F. et al. Immune infiltration profiling in gastric cancer and their clinical implications. Cancer Sci. 112, 3569\u20133584 (2021).","journal-title":"Cancer Sci."},{"key":"1450_CR120","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/jjco\/hyaf081","volume":"55","author":"I Nakayama","year":"2025","unstructured":"Nakayama, I. Therapeutic strategy for scirrhous type gastric cancer. Jpn J. Clin. Oncol. 55, 860\u2013870 (2025).","journal-title":"Jpn J. Clin. Oncol."},{"key":"1450_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao, W. et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark. Res. 10, 38 (2022).","journal-title":"Biomark. Res."},{"key":"1450_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8, 100762 (2023).","journal-title":"ESMO Open"},{"key":"1450_CR123","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251344804","volume":"17","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto, K., Nakayama, I. & Shitara, K. Emerging evidence of targeting non-oncogenic drivers for gastric cancer: claudin18.2 and beyond. Ther. Adv. Med. Oncol. 17, 17588359251344804 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1450_CR124","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471716","volume":"45","author":"I Nakayama","year":"2025","unstructured":"Nakayama, I. & Shitara, K. Cell-based therapies in GI cancers: current landscape and future directions. Am. Soc. Clin. Oncol. Educ. Book. 45, e471716 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"1450_CR125","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","volume":"156","author":"F Kinugasa","year":"2024","unstructured":"Kinugasa, F. et al. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J. Pharmacol. Sci. 156, 161\u2013170 (2024).","journal-title":"J. Pharmacol. Sci."},{"key":"1450_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo6783","volume":"8","author":"R Hashimoto","year":"2022","unstructured":"Hashimoto, R. et al. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing claudin-5 expression. Sci. Adv. 8, eabo6783 (2022).","journal-title":"Sci. Adv."},{"key":"1450_CR127","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2021.06.009","volume":"336","author":"K Tachibana","year":"2021","unstructured":"Tachibana, K. et al. Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood\u2013brain barrier permeability for drug delivery to the brain in a non-human primate. J. Control. Rel. 336, 105\u2013111 (2021).","journal-title":"J. Control. Rel."},{"key":"1450_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15108-y","volume":"7","author":"A Watari","year":"2017","unstructured":"Watari, A. et al. Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay. Sci. Rep. 7, 14514 (2017).","journal-title":"Sci. Rep."},{"key":"1450_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/srep11333","volume":"5","author":"H Takeda","year":"2015","unstructured":"Takeda, H. et al. Production of monoclonal antibodies against GPCR using cell-free synthesized GPCR antigen and biotinylated liposome-based interaction assay. Sci. Rep. 5, 11333 (2015).","journal-title":"Sci. Rep."},{"key":"1450_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114255","volume":"159","author":"I Fatima","year":"2023","unstructured":"Fatima, I. et al. Identification and characterization of a first-generation inhibitor of claudin-1 in colon cancer progression and metastasis. Biomed. Pharmacother. 159, 114255 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1450_CR131","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbrc.2016.06.025","volume":"477","author":"Y Hashimoto","year":"2016","unstructured":"Hashimoto, Y. et al. Generation and characterization of a human\u2013mouse chimeric antibody against the extracellular domain of Claudin-1 for cancer therapy using a mouse model. Biochem. Biophys. Res. Commun. 477, 91\u201395 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1450_CR132","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jhep.2025.08.005","volume":"83","author":"F Del Zompo","year":"2025","unstructured":"Del Zompo, F. et al. Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis. J. Hepatol. 83, 1305\u20131319 (2025).","journal-title":"J. Hepatol."},{"key":"1450_CR133","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nbt.3179","volume":"33","author":"L Mailly","year":"2015","unstructured":"Mailly, L. et al. Clearance of persistent hepatitis C virus infection in humanized mice using a Claudin-1-targeting monoclonal antibody. Nat. Biotechnol. 33, 549\u2013554 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1450_CR134","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejps.2018.02.016","volume":"117","author":"Y Hashimoto","year":"2018","unstructured":"Hashimoto, Y. et al. Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2. Eur. J. Pharm. Sci. 117, 161\u2013167 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1450_CR135","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/j.1349-7006.2009.01239.x","volume":"100","author":"M Suzuki","year":"2009","unstructured":"Suzuki, M. et al. Therapeutic antitumor efficacy of monoclonal antibody against claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100, 1623\u20131630 (2009).","journal-title":"Cancer Sci."},{"key":"1450_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.266","volume":"4","author":"Y Hashimoto","year":"2016","unstructured":"Hashimoto, Y. et al. Efficacy and safety evaluation of Claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody. Pharmacol. Res. Perspect. 4, e00266 (2016).","journal-title":"Pharmacol. Res. Perspect."},{"key":"1450_CR137","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.canlet.2015.08.019","volume":"369","author":"M Kuwada","year":"2015","unstructured":"Kuwada, M. et al. Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer. Cancer Lett. 369, 212\u2013221 (2015).","journal-title":"Cancer Lett."},{"key":"1450_CR138","first-page":"4555","volume":"30","author":"M Kato-Nakano","year":"2010","unstructured":"Kato-Nakano, M. et al. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. Anticancer. Res. 30, 4555\u20134562 (2010).","journal-title":"Anticancer. Res."},{"key":"1450_CR139","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1124\/jpet.114.216911","volume":"351","author":"X Li","year":"2014","unstructured":"Li, X. et al. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy. J. Pharmacol. Exp. Ther. 351, 206\u2013213 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1450_CR140","doi-asserted-by":"publisher","first-page":"10405","DOI":"10.1128\/JVI.01691-13","volume":"87","author":"I Fofana","year":"2013","unstructured":"Fofana, I. et al. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J. Virol. 87, 10405\u201310410 (2013).","journal-title":"J. Virol."},{"key":"1450_CR141","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1053\/j.gastro.2010.05.073","volume":"139","author":"I Fofana","year":"2010","unstructured":"Fofana, I. et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139, 953\u2013964.e1-4 (2010).","journal-title":"Gastroenterology"},{"key":"1450_CR142","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1124\/jpet.117.242214","volume":"363","author":"M Takigawa","year":"2017","unstructured":"Takigawa, M. et al. Creation of a claudin-2 binder and its tight junction-modulating activity in a human intestinal model. J. Pharmacol. Exp. Ther. 363, 444\u2013451 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1450_CR143","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.117.243014","volume":"363","author":"Y Hashimoto","year":"2017","unstructured":"Hashimoto, Y. et al. Claudin-5-binders enhance permeation of solutes across the blood\u2013brain barrier in a mammalian model. J. Pharmacol. Exp. Ther. 363, 275\u2013283 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1450_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu, J. et al. Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int. 25, 313 (2025).","journal-title":"Cancer Cell Int."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01450-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01450-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:02:58Z","timestamp":1787918578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01450-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":144,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01450-2","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"15 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.N., S.M. and M.K. declare no competing interests. I.N. has received research funding from Astellas, Ono Pharmaceutical, Merck Sharp & Dohme, Daiichi Sankyo, Boehringer Ingelheim and Chugai Pharmaceutical. I.N. has received lecture fees from Astellas, Ono Pharmaceutical, Bristol Myers Squibb, Merck Sharp & Dohme, Daiichi Sankyo, Taiho Pharmaceutical and AstraZeneca outside the submitted work. I.N. has received honoraria for advisory board participation from AstraZeneca and Amgen.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}